Authors
Latest:
Dr. Suarez Mora On Sequential Sampling of IP Fluid During ChemotherapyAdria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.
Latest:
Dr. Wiestner Discusses Findings From the Phase III HELIOS TrialAdrian Wiestner, MD, PhD, National Institutes of Health, National Heart, Lung, and Blood Services, discusses findings from the phase III HELIOS trial, which explored the addition of ibrutinib to bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Relapsed/Refractory Multiple Myeloma: Future Directions in CareClosing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.
Latest:
Impairment-Driven Cancer Rehabilitation Improves Survivors' Quality of LifeThe lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.
Latest:
Dr. Phillips Discusses the Treatment of ATLLAdrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.
Latest:
Dr. Ribeiro on the Role of Surgery in Pancreatic CancerAfonso Ribeiro, MD, discusses the role of surgery in treating patients with pancreatic cancer.
Latest:
Dr. Barzi on Combination Regorafenib and Pembrolizumab in MSS CRCAfsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.
Latest:
Ã…ge Schultz, DVM, PhD, Discusses the Cost of Supportive Care MedicineÃ…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.
Latest:
Dr. Paner on HORIZON Trial in Multiple MyelomaAgne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.
Latest:
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell LeukemiaAgnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.
Latest:
Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian CancerThe evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.
Latest:
It's Time to Tackle the Evidence Gap in Lymphoid CancersAlthough CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.
Latest:
Dr. Tarhini on Recent Practice-Changing Clinical Trials in MelanomaAhmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.
Latest:
Robot-Assisted Cystectomy Is Feasible for Many Patients With Bladder CancerTo determine the 10-year oncologic outcomes and recurrence patterns after robot-assisted radical cystectomy, a group within the Department of Urology at Roswell Park Comprehensive Cancer Center performed a retrospective review.
Latest:
Dr. Galal on Managing AEs Linked With CAR T-Cell TherapyAhmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.
Latest:
Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian CancerAhmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.
Latest:
Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCCAhmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.
Latest:
Dr. Dogan on Updated WHO Classifications in DLBCLAhmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits ManagementPayers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.
Latest:
Dr. He on the Results of the LEGACY Study Examining Y-90 in HCCRuth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.
Latest:
Advanced Biliary Tract Cancers: Novel Biomarker StrategiesClosing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Latest:
Improving Care in Multiple Myeloma: Unmet Needs and Future DirectionsClosing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.
Latest:
Dr. Chari on the Role of MRD Testing in Multiple MyelomaAjai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.
Latest:
Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple MyelomaAjay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Latest:
Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1Dr Nooka reviews the patient reported outcomes from the MajesTEC-1 trial in patients with relapsed/refractory multiple myeloma.
